| Endometrial and Cervical Cancer Treatments | Lifetime | 2 | IT 1 | 99.92 |
| Intraperitoneal and Appendiceal Malignancies | Lifetime | 3 | IT 1 | 99.85 |
| Ovarian cancer diagnosis and treatment | Lifetime | 7 | IT 1 | 99.90 |
| Uterine Myomas and Treatments | Lifetime | 12 | IT 4 | 99.80 |
| Endometriosis Research and Treatment | Lifetime | 24 | IT 7 | 99.69 |
| PARP inhibition in cancer therapy | Lifetime | 24 | IT 1 | 99.52 |
| Estrogen and related hormone effects | Lifetime | 110 | IT 2 | 99.41 |
| Cervical Cancer and HPV Research | Lifetime | 84 | IT 2 | 99.45 |
| Colorectal and Anal Carcinomas | Lifetime | 71 | IT 2 | 99.24 |
| Minimally Invasive Surgical Techniques | Lifetime | 27 | IT 3 | 99.15 |
| BRCA gene mutations in cancer | Lifetime | 175 | IT 3 | 98.52 |
| Cancer Treatment and Pharmacology | Lifetime | 445 | IT 35 | 98.73 |
| Cancer-related Molecular Pathways | Lifetime | 421 | IT 13 | 98.52 |
| Gynecological conditions and treatments | Lifetime | 106 | IT 22 | 98.44 |
| Cancer Mechanisms and Therapy | Lifetime | 203 | IT 11 | 97.81 |
| Reproductive System and Pregnancy | Lifetime | 505 | IT 23 | 97.44 |
| Multiple and Secondary Primary Cancers | Lifetime | 267 | IT 26 | 97.24 |
| Sarcoma Diagnosis and Treatment | Lifetime | 742 | IT 56 | 97.50 |
| Lymphoma Diagnosis and Treatment | Lifetime | 982 | IT 74 | 97.81 |
| HER2/EGFR in Cancer Research | Lifetime | 542 | IT 36 | 97.79 |
| Renal cell carcinoma treatment | Lifetime | 587 | IT 47 | 97.64 |
| Cancer, Lipids, and Metabolism | Lifetime | 887 | IT 32 | 96.97 |
| Cytokine Signaling Pathways and Interactions | Lifetime | 680 | IT 13 | 96.69 |
| Appendicitis Diagnosis and Management | Lifetime | 463 | IT 32 | 96.23 |
| Lung Cancer Research Studies | Lifetime | 938 | IT 62 | 97.00 |
| Cancer Risks and Factors | Lifetime | 486 | IT 24 | 96.81 |
| Intestinal and Peritoneal Adhesions | Lifetime | 277 | IT 31 | 95.27 |
| Pelvic and Acetabular Injuries | Lifetime | 711 | IT 13 | 96.43 |
| Ectopic Pregnancy Diagnosis and Management | Lifetime | 379 | IT 15 | 95.52 |
| Hernia repair and management | Lifetime | 772 | IT 39 | 94.36 |
| Microtubule and mitosis dynamics | Lifetime | 983 | IT 15 | 94.67 |
| Bioactive Compounds and Antitumor Agents | Lifetime | 847 | IT 28 | 92.84 |
| Cancer, Stress, Anesthesia, and Immune Response | Lifetime | 566 | IT 33 | 91.22 |
| Phytoestrogen effects and research | Lifetime | 635 | IT 22 | 92.53 |
| Testicular diseases and treatments | Lifetime | 982 | IT 50 | 91.57 |
| Gestational Trophoblastic Disease Studies | Lifetime | 788 | IT 38 | 81.68 |
| Lymphatic Disorders and Treatments | Lifetime | 494 | IT 15 | 67.66 |
| Omental and Epiploic Conditions | Lifetime | 185 | IT 10 | 65.60 |
| Mechanisms of cancer metastasis | Lifetime | 731 | IT 26 | 64.50 |
| Beetle Biology and Toxicology Studies | Lifetime | 697 | IT 32 | 50.95 |
| Ovarian cancer diagnosis and treatment | 2021-2025 | 1 | IT 1 | 99.98 |
| Endometrial and Cervical Cancer Treatments | 2021-2025 | 1 | IT 1 | 99.97 |
| Intraperitoneal and Appendiceal Malignancies | 2021-2025 | 2 | IT 1 | 99.59 |
| Uterine Myomas and Treatments | 2021-2025 | 3 | IT 2 | 99.76 |
| BRCA gene mutations in cancer | 2021-2025 | 6 | IT 1 | 99.52 |
| Cervical Cancer and HPV Research | 2021-2025 | 9 | IT 2 | 99.57 |
| Endometriosis Research and Treatment | 2021-2025 | 11 | IT 6 | 99.50 |
| PARP inhibition in cancer therapy | 2021-2025 | 8 | IT 3 | 99.70 |
| Colorectal and Anal Carcinomas | 2021-2025 | 16 | IT 3 | 99.00 |
| Pelvic and Acetabular Injuries | 2021-2025 | 65 | IT 3 | 96.56 |
| Pelvic floor disorders treatments | 2021-2025 | 102 | IT 12 | 96.61 |
| Cancer Risks and Factors | 2021-2025 | 78 | IT 6 | 95.35 |
| Colorectal Cancer Surgical Treatments | 2021-2025 | 277 | IT 35 | 95.25 |
| Gynecological conditions and treatments | 2021-2025 | 52 | IT 22 | 95.68 |
| Molecular Biology Techniques and Applications | 2021-2025 | 104 | IT 2 | 89.87 |
| Anorectal Disease Treatments and Outcomes | 2021-2025 | 123 | IT 19 | 93.28 |
| Cancer Genomics and Diagnostics | 2021-2025 | 938 | IT 73 | 94.65 |
| Ectopic Pregnancy Diagnosis and Management | 2021-2025 | 58 | IT 8 | 92.95 |
| Renal cell carcinoma treatment | 2021-2025 | 340 | IT 62 | 94.68 |
| Reproductive System and Pregnancy | 2021-2025 | 242 | IT 13 | 93.55 |
| Sarcoma Diagnosis and Treatment | 2021-2025 | 390 | IT 40 | 93.32 |
| Reproductive Biology and Fertility | 2021-2025 | 634 | IT 47 | 91.93 |
| Minimally Invasive Surgical Techniques | 2021-2025 | 58 | IT 12 | 88.30 |
| Appendicitis Diagnosis and Management | 2021-2025 | 295 | IT 48 | 86.66 |
| Genetic factors in colorectal cancer | 2021-2025 | 688 | IT 82 | 89.41 |
| Toxin Mechanisms and Immunotoxins | 2021-2025 | 123 | IT 7 | 84.38 |
| Surgical Simulation and Training | 2021-2025 | 415 | IT 41 | 88.14 |
| Testicular diseases and treatments | 2021-2025 | 159 | IT 14 | 86.55 |
| Estrogen and related hormone effects | 2021-2025 | 340 | IT 25 | 84.05 |
| Multiple and Secondary Primary Cancers | 2021-2025 | 337 | IT 28 | 81.56 |
| Cancer Mechanisms and Therapy | 2021-2025 | 440 | IT 21 | 82.24 |
| Ureteral procedures and complications | 2021-2025 | 282 | IT 42 | 82.10 |
| Pregnancy-related medical research | 2021-2025 | 389 | IT 26 | 78.80 |
| Surgical site infection prevention | 2021-2025 | 400 | IT 19 | 76.15 |
| Anatomy and Medical Technology | 2021-2025 | 495 | IT 43 | 77.84 |
| Diverticular Disease and Complications | 2021-2025 | 641 | IT 96 | 77.02 |
| Hernia repair and management | 2021-2025 | 926 | IT 67 | 73.42 |
| Management of metastatic bone disease | 2021-2025 | 891 | IT 79 | 70.87 |
| Angiogenesis and VEGF in Cancer | 2021-2025 | 871 | IT 37 | 57.09 |
| Gestational Trophoblastic Disease Studies | 2021-2025 | 410 | IT 51 | 50.36 |
| Chemotherapy-related skin toxicity | 2021-2025 | 659 | IT 52 | 42.13 |
| Female Genital Mutilation/Cutting Issues | 2021-2025 | 604 | IT 24 | 41.12 |
| Genetics, Bioinformatics, and Biomedical Research | 2021-2025 | 960 | IT 10 | 35.76 |
